Compare NetEase Inc (NTES) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetEase Inc vs ResMed Inc. — how do they compare? NetEase Inc trades at $123.03 (market cap $76.09B), while ResMed Inc. trades at $225.92 (market cap $31.89B). The key difference: NetEase Inc is far larger — about 2.4× ResMed Inc.'s market cap, and NetEase Inc pays the higher dividend (2.45%). Which is the better fit depends on your goals — on Pluang, investors hold NetEase Inc for 74 Days and ResMed Inc. for 51 Days on average.
| NTES | RMD | |
|---|---|---|
Market Cap | $76.09B | $31.89B |
Volume | 486,447 | 618,314 |
Sector | Technology | Health |
52-Week High | $152.85 | $277.88 |
52-Week Low | $109.26 | $182.82 |
Typical Hold Time | 74 Days | 51 Days |
Enterprise Value | $51.81B | $31.24B |
Dividend Yield | 2.45% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NetEase (NTES) trades at $120.61, up 1.29% with neutral technical signals and mixed earnings performance. The company maintains strong fundamentals with $112.63B revenue, 27.88% net margin, and robust cash flow. Recent Q2 2026 earnings missed expectations despite revenue growth, while analyst consensus remains strongly bullish with $168 price target representing 39% upside potential.
NTES presents compelling value with reasonable valuation multiples (P/E 16.06, EV/EBITDA 8.15) and strong profitability metrics. Key risks include earnings volatility and competitive pressures in gaming. The stock offers attractive upside based on analyst targets, supported by the company's solid balance sheet and consistent dividend growth track record.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical signal and strong fundamentals. Revenue grew to $5.15B in 2025, with net income at $1.40B and a 26.94% net margin. Recent earnings beats and a 12-14% EPS growth outlook support momentum. The stock is near its pivot point of $227, with support at $225 and resistance at $228.
Outlook is positive with analyst consensus at Buy and a $242.70 price target. Risks include competitive pressures and ongoing legal investigations. Institutional buying and solid cash flow growth underpin the bullish case, though macroeconomic and regulatory factors warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
